This company listing is no longer active
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
OKYO Pharma 과거 수익 실적
과거 기준 확인 0/6
OKYO Pharma has been growing earnings at an average annual rate of 39.4%, while the Biotechs industry saw earnings growing at 7.2% annually.
주요 정보
39.4%
수익 성장률
62.4%
EPS 성장률
Biotechs 산업 성장 | 11.5% |
매출 성장률 | n/a |
자기자본 수익률 | n/a |
순이익 | n/a |
최근 수익 업데이트 | 30 Sep 2022 |
최근 과거 실적 업데이트
업데이트 없음
Recent updates
Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?
Nov 26Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?
Jan 27Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation
Sep 22We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth
Mar 17We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow
Dec 02수익 및 비용 분석
OKYO Pharma 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Sep 22 | 0 | -7 | 0 | 3 |
30 Jun 22 | 0 | -5 | 0 | 2 |
31 Mar 22 | 0 | -4 | 0 | 1 |
31 Dec 21 | 0 | -4 | 0 | 1 |
30 Sep 21 | 0 | -4 | 0 | 0 |
30 Jun 21 | 0 | -3 | 0 | 0 |
31 Mar 21 | 0 | -3 | 0 | 0 |
31 Dec 20 | 0 | -1 | 0 | 0 |
30 Sep 20 | 0 | 0 | 0 | 0 |
30 Jun 20 | 0 | -1 | 0 | 0 |
31 Mar 20 | 0 | -1 | 0 | 0 |
31 Dec 19 | 0 | -3 | 0 | 1 |
30 Sep 19 | 0 | -4 | 0 | 2 |
30 Jun 19 | 0 | -4 | 0 | 2 |
31 Mar 19 | 0 | -4 | 0 | 2 |
31 Dec 18 | 0 | -3 | 0 | 1 |
30 Sep 18 | 0 | -2 | 0 | 1 |
30 Jun 18 | 0 | -11 | 0 | 1 |
31 Mar 18 | 0 | -20 | 0 | 0 |
31 Dec 17 | 0 | -20 | 0 | 0 |
30 Sep 17 | 0 | -19 | 0 | 0 |
30 Jun 17 | 0 | -10 | 0 | 0 |
31 Mar 17 | 0 | 0 | 0 | 0 |
31 Dec 16 | 0 | 0 | 0 | 0 |
30 Sep 16 | 0 | 0 | 1 | 0 |
양질의 수익: OKYO is currently unprofitable.
이익 마진 증가: OKYO is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: OKYO is unprofitable, but has reduced losses over the past 5 years at a rate of 39.4% per year.
성장 가속화: Unable to compare OKYO's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: OKYO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7%).
자기자본 수익률
높은 ROE: OKYO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.